Functional Role and Prognostic Significance of CD157 in Ovarian Carcinoma

Erika Ortolan, Riccardo Arisio, Simona Morone, Paola Bovino, Nicola Lo-Buono, Giulia Nacci, Rossella Parrotta, Dionyssios Katsaros, Ida Rapa, Giuseppe Migliaretti, Enza Ferrero, Marco Volante (+1 others)
2010 Journal of the National Cancer Institute  
Results CD157 was expressed by ovarian cancer cells and mesothelium, and it potentiated the adhesion, migration, and invasion of serous ovarian cancer cells through different extracellular matrices. CD157-transfected ovarian cancer cells migrated twice as much as CD157-negative control cells (P = .001). Blockage of CD157 inhibited mesothelial invasion by serous ovarian cancer cells in a three-dimensional model. CD157 was expressed in 82 (93%) of the 88 epithelial ovarian cancer tissue
more » ... In serous ovarian cancer, patients with CD157 H scores of 60 or greater had statistically significantly shorter disease-free survival and overall survival than patients with lower CD157 H scores (CD157 H score ≥60 vs <60: median disease-free survival = 18 months, 95% confidence interval [CI] = 5.92 to 30.07 vs unreached, P = .005; CD157 H score ≥60 vs <60: median overall survival = 45 months, 95% CI = 21.21 to 68.79 vs unreached, P = .024). Multivariable Cox regression showed that CD157 is an independent prognostic factor for recurrence (hazard ratio of disease recurrence = 3.01, 95% CI = 1.35 to 6.70, P = .007) and survival (hazard ratio of survival = 3.44, 95% CI = 1.27 to 9.31, P = .015). Conclusions CD157 plays a pivotal role in the control of ovarian cancer cell migration and peritoneal invasion, and it may be clinically useful as a prognostic tool and therapeutic target.
doi:10.1093/jnci/djq256 pmid:20639476 fatcat:4ul2smfu4nfxhnhjnmqspzm5ay